Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix® 30 Previously Treated With Mixtard® Insulins

Novo Nordisk

Status: Completed

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: biphasic insulin aspart 30

Study type: Observational

Funder types: Industry

Identifiers

NCT00657319

BIASP-1939

Details and patient eligibility

About

This observational study is conducted in Europe. The objective of this retrospective observational cohort analysis is to assess the changes of glycaemic control and quality of care in those Type 2 diabetic patients who were previously treated with Mixtard® insulins after 6 months of their switch to analog premix insulin NovoMix® 30 therapy.

Enrollment: 3,495 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects diagnosed with type 2 diabetes previously treated with BHI for at least 12 months
• Analogue premix administration for the last 6 months

Exclusion criteria

• Known or suspected allergy to insulin aspart
• Newly diagnosed diabetes

Trial design

3,495 participants in 1 patient group

A

Treatment:

Drug: biphasic insulin aspart 30